文献速递淋巴瘤

滤泡性淋巴瘤一线治疗:改变当前实践需要什么?

Frontline treatment of follicular lymphoma: what will it take to change current practice?
PubMed 文献 · Blood · 2025-01-01

滤泡性淋巴瘤是最常见的惰性淋巴瘤亚型。尽管过去数十年多项试验显示抗CD20维持治疗和新型糖工程抗CD20抗体等新一线策略可改善无进展生存期,但尚无标准化方案被广泛采用。本综述探讨当前和未来旨在重塑一线治疗范式的策略,包括基于风险或反应适应的个体化设计、开发新的预测性而非预后性工具、减少不良事件以提高健康相关生活质量,以及潜在使用T细胞衔接疗法改善最高危患者的生存。

要点

  • 尽管新一线策略改善无进展生存期,但无标准化方案被广泛采用,可能与感染性不良事件增加及缺乏总生存获益有关。
  • 滤泡性淋巴瘤预后高度异质,现有预后评分(FLIPI、FLIPI2、PRIMA-PI、m7-FLIPI、FLEX、23基因评分等)均不能可靠识别约20%在一线免疫化疗后10年内死亡的患者。
  • 当前预后模型主要用作临床试验交叉比较和分层的工具。

核心结论

  • 尽管新一线策略改善无进展生存期,但尚无标准化方案被广泛采用;当前预后模型主要用作临床试验交叉比较和分层的工具。

研究设计与样本

  • 综述,检索范围未报告。

主要发现

  • 过去数十年多项试验显示抗CD20维持治疗和新型糖工程抗CD20抗体等新一线策略可改善无进展生存期。
  • 这些治疗与感染性不良事件增加相关,尤其在COVID-19大流行期间。
  • 长期随访未显示总生存获益。
  • 已提出多种预后评分(FLIPI、FLIPI2、PRIMA-Prognostic Index、m7-FLIPI、FLEX、23-gene score等),但均不能可靠识别约20%在一线免疫化疗后10年内死亡的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma is the most common subtype of indolent lymphoma. Despite multiple trials over the past decades showing improved progression-free survival with new first-line therapeutic strategies, such as anti-CD20 maintenance therapy and new glycoengineered anti-CD20 antibodies, no standardized approach has been widely adopted in routine clinical practice. Several factors may explain this, including the increased incidence of infectious adverse events associated with these therapies, particularly during the COVID-19 pandemic, and the lack of overall survival benefit despite long-term follow-up. A consensus has emerged acknowledging the high prognostic variability of follicular lymphoma, which complicates the adoption of a one-size-fits-all first-line treatment strategy. A plethora of prognostic scores (Follicular Lymphoma International Prognostic Index [FLIPI], FLIPI2, PRIMA-Prognostic Index, m7-FLIPI, FLEX [Follicular Lymphoma Evaluation Index], 23-gene score, etc) has been proposed but none can reliably identify the ∼20% of patients who will die within 10 years of first-line immunochemotherapy and for whom a critical medical need remains despite recent therapeutic improvements. Consequently, current prognostic models mainly serve as tools to cross-compare and stratify clinical trials. In this review, we highlight current and future strategies aimed at reshaping frontline treatment paradigms to improve outcomes, including tailored approaches based on risk- or response-adapted designs, development of new predictive, rather than prognostic, tools, approaches to reduce adverse events to enhance health-related quality of life, and the potential use of T-cell-engaging therapies to improve survival in the highest risk patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bachy E, Linton K. Frontline treatment of follicular lymphoma: what will it take to change current practice? Blood. 2025. PMID: 39869829. doi:10.1182/blood.2024026019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。